YU Miao, MAO Junqin. Functional investigation of a new targeting gene delivery system of miRNA-34a nano-complexes into prostate cancer cell lines[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 539-543. doi: 10.3969/j.issn.1006-0111.2015.06.016
| Citation:
|
YU Miao, MAO Junqin. Functional investigation of a new targeting gene delivery system of miRNA-34a nano-complexes into prostate cancer cell lines[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 539-543. doi: 10.3969/j.issn.1006-0111.2015.06.016
|
Functional investigation of a new targeting gene delivery system of miRNA-34a nano-complexes into prostate cancer cell lines
- Received Date: 2014-12-16
- Rev Recd Date:
2015-04-23
-
Abstract
Objective To construct a gene delivery carrier with aptamer-polyethylene glycol-dendrimer-polyamidoamine (APT-PEG-PAMAM), forming nanoparticles to specifically target prostate cancer cell lines, carrying prostate cancer cell proliferative suppressor microRNA: miRNA-34a. We investigated the transfection efficiency of this gene delivery system as well as functionally studied its inhibitory effect on prostate cancer (PCa) cell proliferation. Methods The construction of APT-PEG-PAMAM gene carrier was identified and confirmed by nuclear magnetic resonance (NMR). The nano-complex sizes and zeta potential of APT-PEG-PAMAM gene carrier complexes were measured by zeta sizer. The efficiency of gene transfection of APT-PEG-PAMAM / miRNA nano-complexes were investigated by measuring the expression miRNA-34a in prostate cancer cells (PC3 and LNCaP);the PCa specific cell proliferation inhibition of APT-PEG-PAMAM / miRNA-34a nano-complexes were investigated by measuring CCK-8 cell proliferation inhibition experiments by comparing with APT-PEG-PAMAM and APT-PEG-PAMAM / miRNA-34a nano-complexes. Results NMR Results demonstrated that APT-PEG-PAMAM / miRNA-34a nano-complexes were successfully synthesized by structural identification. Qualitative and quantitative transfection efficiency experiments data show that the cellular uptake of vectors were concentration-dependent, after the APT further modified it significantly and increased the LNCaP cell transfection efficiency and specificity of PCa cells targeting ability. CCK8 cell proliferation assay data indicated that APT-PEG-PAMAM/miRNA-34a has the anti-PCa cells effect. Conclusion APT-PEG-PAMAM/miRNA-34a may prove to see its efficacy for near future in pre-clinical and clinical study on the treatment of PCa.
-
References
|
[1]
|
陈万青,郑荣寿,曾红梅,等. 2011年中国恶性肿瘤发病和死亡分析[J]. 中国肿瘤,2015,24(1):1-10. |
|
[2]
|
韩苏军,张思维,陈万青,等. 中国前列腺癌发病现状和流行趋势分析[J]. 临床肿瘤学杂志,2013,18(4):330-334. |
|
[3]
|
Siegel R, Ma J, Zou Z, et al. Cancer statistics[J]. CA Cancer J Clin,2014,64(1):9-29. |
|
[4]
|
Khraiwesh B, Arif MA, Seumel GI,et al. Transcriptional control of gene expression by microRNAs[J]. Cell, 2010, 140(1):111-122. |
|
[5]
|
Gong MC, Chang SS, Sadelain M, et al. Prostate specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers[J]. Cancer Metastasis Rev, 1999, 18:483 490. |
|
[6]
|
Nery AA, Wrenger C, Ulrich H. Recognition of biomarkers and cell-specific molecular signatures: aptamers as capture agents[J]. J Sep Sci,2009, 32(10):1523-1530. |
|
[7]
|
武 鑫,蔡 溱,朱全刚,等. YPSMA-1单克隆抗体修饰的树突状高分子前列腺癌靶向基因递送载体[J]. 中国药学杂志,2012,47(6):418-422. |
|
[8]
|
Wu X, Ding B, Gao J, et al. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy[J]. Int J Nanomedicine,2011, 6:1747-1756. |
|
[9]
|
Hinson DL, Webber RJ. Miniaturization of the BCA protein assay[J]. Biotechniques,1988, 6(1):14-19. |
-
-
Proportional views
-
DownLoad: